All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Improving outcomes for people of color with chronic plaque psoriasis including scalp involvement
with Paolo Gisondi, Andrew Alexis, and Mona Shahriari
Thursday, February 6, 2025
16:00-17:00 GMT
This independent educational activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Phase II GAP trial: Guselkumab in palmoplantar pustulosis
|
Guselkumab, an IL-23 inhibitor, has been approved for the treatment of palmoplantar pustulosis in Japan.1 Wilsmann-Theis et al.1 published the results of a phase II GAP trial (EUDRA-CT-No. 2018-004451-20) evaluating the efficacy and safety of 100 mg subcutaneous guselkumab in 50 European patients with moderate-to-severe palmoplantar pustulosis in the Journal of the American Academy of Dermatology International. The primary endpoint was reduction in palmoplantar pustulosis psoriasis area and severity index (PPPASI) at Week 24.1 |
| Key learnings |
| Guselkumab met the primary endpoint resulting in a median PPPASI reduction of 59.6% at Week 24 (p < 0.001). The proportions of patients achieving PPPASI-50 and PPPASI-75 at Week 24 were 66.0% and 34.0%, respectively. |
| At Week 24, the median DLQI decreased from 15 to 5 (p < 0.001). Changes in IL-19 serum levels at Week 4 were associated with a reduction in PPPASI (p < 0.01) and pustule count (p < 0.05) at Week 24. |
| Overall, 102 TEAEs occurred in 74% of patients and were mild to moderate in severity. No deaths were reported due to guselkumab. |
| Results suggest that guselkumab may be a potential therapeutic choice for palmoplantar pustulosis, particularly within the Caucasian population. |
Abbreviations: DLQI, Dermatology Life Quality Index; IL, interleukin; PPPASI, Palmoplantar Pustulosis Area and Severity Index; PPPASI-50, 50% improvement in Palmoplantar Pustulosis Area and Severity Index; PPPASI-75, 75% improvement in Palmoplantar Pustulosis Area and Severity Index TEAE, treatment-emergent adverse event.
- Wilsmann-Theis D, Patt S, Pinter A, et al. Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study). JAAD Int. 2024;18:69-78. DOI: 10.1016/j.jdin.2024.09.001
More about...
Your opinion matters
13 votes - 22 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox